The pharmaceutical industry has emerged as a central pillar of economic security, national resilience, and geopolitical competition. Once viewed primarily through the lens of healthcare delivery, pharmaceutical production is increasingly recognized as a strategic asset comparable to energy infrastructure, semiconductor manufacturing, and critical minerals supply chains. Recent disruptions caused by the COVID-19 pandemic, growing geopolitical tensions between China and the West, and the weaponization of economic interdependence have exposed the vulnerabilities of highly concentrated global pharmaceutical supply chains.
Today, approximately 55% of global Active Pharmaceutical Ingredient (API) production is concentrated in China and India. This concentration creates systemic risks for governments seeking to ensure uninterrupted access to critical medicines during crises. At the same time, China has integrated biotechnology and pharmaceutical manufacturing into its long-term national development strategy, mobilizing state-backed financing, industrial planning mechanisms, and domestic market advantages to strengthen its global position.
The United States has responded with a different model, combining tariffs, tax incentives, strategic procurement policies, and regulatory acceleration to attract pharmaceutical investment and reduce dependency on foreign suppliers. Europe, meanwhile, finds itself at a crossroads. Despite maintaining world-class research institutions, advanced regulatory systems, and globally competitive pharmaceutical firms, the European Union faces growing concerns that it may repeat the industrial decline previously witnessed in sectors such as steel, solar panels, battery manufacturing, and electric vehicles.
The emergence of initiatives such as the Critical Medicines Act (CMA), the Industrial Accelerator Act (IAA), and the forthcoming Biotech Act reflects a significant shift in European thinking. These initiatives seek to strengthen domestic production capacity and reduce strategic vulnerabilities. However, the challenge lies in balancing resilience objectives with economic competitiveness, single market cohesion, and international trade commitments.
This paper argues that pharmaceutical sovereignty cannot be achieved through protectionism alone. Sustainable resilience requires a broader strategy built upon innovation leadership, diversified supply chains, strategic partnerships with trusted allies, and regulatory modernization.
The New Geopolitics of Medicines
For decades, globalization encouraged pharmaceutical companies to relocate manufacturing activities toward lower-cost jurisdictions. Governments benefited from reduced healthcare expenditures, companies increased profitability, and consumers enjoyed lower prices. However, efficiency often came at the expense of resilience.
The COVID-19 pandemic exposed the consequences of this model. During the early stages of the crisis, countries imposed export restrictions on medical products, personal protective equipment, vaccines, and pharmaceutical ingredients. Policymakers across Europe suddenly realized that access to essential medicines depended heavily on manufacturing facilities located thousands of kilometers away.
What had previously been viewed as an economic issue became a national security concern.
As former European Central Bank President Mario Draghi observed in his 2025 report on European competitiveness:
“Strategic dependencies are no longer isolated economic vulnerabilities; they have become geopolitical liabilities.”
The pharmaceutical sector exemplifies this transformation. Critical medicines, antibiotics, cancer treatments, and essential hospital products increasingly depend on supply chains that traverse geopolitical fault lines.
China’s State-Led Pharmaceutical Expansion
China’s rise as a pharmaceutical powerhouse did not occur accidentally. It was the result of deliberate state strategy.
Under successive Five-Year Plans, Beijing identified biotechnology, advanced healthcare, and pharmaceutical manufacturing as priority sectors critical to national development and global influence. Massive state investments, favorable regulatory frameworks, public-private partnerships, and preferential financing enabled Chinese companies to scale production rapidly.
By 2025, China had become the world’s largest producer of pharmaceutical ingredients and one of the fastest-growing biotechnology markets globally. The country’s domestic healthcare market—serving over 1.4 billion people—provides an unparalleled platform for industrial expansion.
Chinese President Xi Jinping has repeatedly emphasized biotechnology as a strategic frontier, declaring that:
“Scientific and technological self-reliance is the foundation of national strength.”
Unlike traditional market economies, China can simultaneously mobilize industrial policy, public procurement, state financing, and regulatory authority toward long-term strategic objectives.
This integrated model creates structural advantages that are difficult for competitors to replicate.
The American Response: Reindustrialization Through Incentives
The United States has adopted a markedly different approach.
Rather than relying primarily on direct state ownership or centralized industrial planning, Washington has focused on creating incentives that attract private investment. Tax credits, reshoring subsidies, accelerated FDA approval pathways, and procurement preferences have become key instruments of industrial policy.
The broader objective extends beyond healthcare.
It is part of a wider strategy aimed at reducing strategic dependence on China across critical sectors including semiconductors, batteries, artificial intelligence, and pharmaceuticals.
According to the White House Office of Science and Technology Policy:
“Supply chain resilience is national security.”
This framing has enabled bipartisan support for measures that would have been politically controversial only a decade ago.
As a result, pharmaceutical manufacturers increasingly view the United States as an attractive destination for new investments, particularly in advanced biologics and next-generation therapeutics.
Europe’s Strategic Dilemma
Europe’s challenge differs fundamentally from that of either China or the United States.
The European Union possesses world-leading pharmaceutical companies, globally respected regulatory institutions, and a highly educated scientific workforce. However, it also faces structural disadvantages that threaten its long-term competitiveness.
These include fragmented national reimbursement systems, slower regulatory processes, lower venture capital availability compared with the United States, and significant differences in healthcare pricing policies across member states.
The risk is not immediate collapse.
Rather, it is gradual erosion.
Europe has already witnessed similar trajectories in steel manufacturing, photovoltaic technologies, and electric vehicle batteries. In each case, Europe began from a position of strength but lost market share as competitors combined scale, state support, and industrial coordination.
The pharmaceutical sector may represent the next battleground.
Policy Recommendations
To avoid strategic decline, European policymakers should focus on four interconnected priorities:
1. Build Resilience Through Diversification
Supply chain security should not mean autarky. Europe should reduce excessive dependence on single suppliers while maintaining diversified international sourcing networks.
2. Strengthen Innovation Ecosystems
Manufacturing follows innovation. Investment in biotechnology research, venture capital markets, and advanced pharmaceutical development remains the most sustainable path toward industrial leadership.
3. Expand Trusted Partnerships
The EU should deepen cooperation with trusted partners including Australia, Switzerland, Canada, Japan, South Korea, and the United Kingdom.
4. Align Industrial and Health Policies
Pricing, reimbursement, procurement, and industrial policy must operate within a coherent strategic framework rather than as separate policy silos.
Conclusion
The future of pharmaceutical security will not be determined solely by factories, regulations, or procurement rules. It will be determined by whether governments can adapt to a world in which economic resilience has become inseparable from geopolitical power.
Europe faces a critical choice. It can pursue narrow localization policies that risk increasing costs and fragmenting markets, or it can develop a broader strategy centered on innovation, diversification, and strategic partnerships.
The outcome will shape not only the future of Europe’s pharmaceutical industry but also its capacity to act as an independent geopolitical actor in an increasingly competitive world.